CMP Pharma has announced the availability of Atorvaliq (atorvastatin calcium), a liquid suspension of Atorvastatin, to treat high cholesterol and specific heart disease or stroke risk factors.
Atorvaliq 20mg/5mL is the first-ever oral suspension to receive Food and Drug Administration (FDA) approval.
The ready-made oral liquid is indicated for patients aged ten years and above.
The medication need not be prepared specially and requires no refrigeration. Offered in a citrus orange flavour, it has a shelf life of two years.
Atorvaliq is claimed to address discrepancies that may be present in compounded or crushed tablet formulations that have not received approval.
CMP Pharma CEO Gerald Sakowski stated: “Atorvaliq is intended for a subset of the patient population that needs atorvastatin but has dysphagia (difficulty swallowing tablets).
“The availability of Atorvaliq gives healthcare providers and appropriate patients a convenient, safe and FDA-approved liquid formulation.”
Atorvaliq is indicated for reducing the risk of myocardial infarction, revascularisation procedures and angina in adults with several risk factors for coronary heart disease.
CMP Pharma is focused on meeting the crucial requirements of niche markets with high-value pharmaceutical products such as these oral liquids.
It has also launched another suspension, Liqrev (sildenafil) 10 mg/mL, a ready-made liquid approved by the FDA.